PRTA - Prothena Corporation plc
| Previous Close | 14.64 |
| Open | 14.60 |
| Bid | 13.20 x 800 |
| Ask | 15.00 x 1200 |
| Day's Range | 14.29 - 14.74 |
| 52 Week Range | 10.43 - 70.00 |
| Volume | 263,519 |
| Avg. Volume | 560,478 |
| Market Cap | 578.032M |
| Beta | 3.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.34 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.29 |
- GlobeNewswire•9 days ago
Notice of Voluntary Dismissal of Class Action Concerning Prothena Corporation
NEW YORK, Aug. 09, 2018-- Levi & Korsinsky, LLP announces that a notice of voluntary dismissal was filed in the securities class action entitled James v. Prothena Corporation in the USDC for the Northern ...
- Zacks•10 days ago
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
- Zacks•11 days ago
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -11.36% and 29.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•11 days ago
Prothena: 2Q Earnings Snapshot
The Dun Laoghaire, Ireland-based company said it had a loss of $1.50 per share. Losses, adjusted for restructuring costs, came to 98 cents per share. The results did not meet Wall Street expectations. ...
- GlobeNewswire•11 days ago
Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update
Net loss was $59.9 million in the second quarter and $108.6 million for the first six months ended June 30, 2018 Net cash from operating and investing activities was $58.0 million in the second quarter ...
- GlobeNewswire•12 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Prothena Corporation Investors and Set a Lead Plaintiff Deadline of October 5, 2018
NEW YORK, Aug. 06, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired common stock of Prothena Corporation between ...
- Zacks•15 days ago
Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.
- GlobeNewswire•18 days ago
Prothena to Report Second Quarter 2018 Financial Results on August 7
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2018 on August 7, 2018 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 7. Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases.
- PR Newswire•25 days ago
Investor Alert: Kaplan Fox Announces Investigation Of Prothena Corporation plc
NEW YORK , July 24, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Prothena Corporation plc ("Prothena" or the "Company") ...
- Business Wire•29 days ago
Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)
National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ: PRTA) securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Prothena investors now have until September 17, 2018 to file a lead plaintiff motion. Investors that suffered losses on their Prothena investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.
- ACCESSWIRE•29 days ago
Free Technical Research on Riot Blockchain and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on RIOT sign up now at www.wallstequities.com/registration. On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), Pulmatrix Inc. (NASDAQ: PULM), and Riot Blockchain Inc. (NASDAQ: RIOT).
- PR Newswire•last month
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Prothena Corporation plc (PRTA) & Lead Plaintiff Deadline - September 17, 2018
NEW YORK , July 18, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" ...
- GlobeNewswire•last month
Labaton Sucharow LLP Files Securities Class Action Lawsuit on Behalf of Prothena Corporation plc Investors
NEW YORK, July 17, 2018-- Labaton Sucharow LLP announces that on July 16, 2018, it filed a securities class action lawsuit on behalf of its client Granite Point Capital against Prothena Corporation plc, ...
- Business Wire•last month
Robbins Arroyo LLP: Prothena Corporation Public Limited Company (PRTA) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Prothena Corporation Public Limited Company (PRTA) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 15, 2015 and April 20, 2018. Prothena develops and sells novel immunotherapy treatment. Prothena's principal asset - NEOD001 - is a monoclonal antibody designed to treat amyloid light chain amyloidosis ("AL amyloidosis"), which can lead to organ failure and death.
- GlobeNewswire•last month
CLASS ACTION DEADLINE MONDAY for PRTA and FLR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, July 16, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
- ACCESSWIRE•last month
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses in Excess of $2,000,000 of Class Action Against Prothena Corporation plc (PRTA) & Lead Plaintiff Deadline - July 16, 2018
NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" or the ...
- GlobeNewswire•last month
SHAREHOLDER ALERT – PRTA SYMC PPG MFGP FLR ATEN REPH DB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, July 15, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
- GlobeNewswire•last month
The Law Offices of Howard G. Smith Reminds Investors of July 16th Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)
Law Offices of Howard G. Smith reminds investors of the July 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (PRTA) securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Prothena investors have until July 16, 2018 to file a lead plaintiff motion. Investors suffering losses on their Prothena investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- GlobeNewswire•last month
CLASS ACTION DEADLINE MONDAY for PRTA and SYMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, July 13, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
- GlobeNewswire•last month
SHAREHOLDER ALERT – PRTA SYMC PPG MFGP FLR DB QCOM NWL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, July 13, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
- GlobeNewswire•last month
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors With Losses in Excess of $2,000,000 of Class Action Against Prothena Corporation plc (PRTA) & Lead Plaintiff Deadline – July 16, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" or the "Company") (PRTA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Prothena securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/prta. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- GlobeNewswire•last month
July 16th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)
LOS ANGELES, July 12, 2018-- National securities litigation law firm Glancy Prongay & Murray LLP reminds investors of the July 16, 2018 deadline to file a lead plaintiff motion in the class action filed ...
- GlobeNewswire•last month
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRTA, PPG, DB, PCG, and TAL
NEW YORK, July 12, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
- ACCESSWIRE•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Prothena Corporation plc of Class Action Lawsuit and Upcoming Deadline - PRTA
NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Prothena Corporation plc ("Prothena" or the "Company") (PRTA) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 18-cv-04035, is on behalf of a class consisting of all persons or entities that purchased Prothena securities between October 15, 2015, and April 20, 2018, inclusive (the "Class Period"). The claims asserted herein are alleged against Prothena and certain of the Company's officers (collectively, "Defendants"), and arise under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5, promulgated thereunder.
- Business Wire•last month
MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (''Prothena” or ''the Company'') (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
